Stimulation of brain AT 1 receptors by Ang II, the main effector peptide of the renin angiotensin system, induces a number of immediate effects comprising a rise in blood pressure, the release of arginine vasopressin (AVP) from the pituitary terminals of magnocellular neurons originating in the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei, sympathetic modulation and drinking (5) . However, Ang II, acting through its central AT 1 receptors, also induces a temporally and spatially highly differentiated expression of transcription factors of the AP-1 and Krox families which is restricted to the subfornical organ (SFO), median preoptic nucleus (MnPO) and the paraventricular (PVN) and supraoptic (SON) hypothalamic nuclei (10, 12, 16, 25) . The distribution of c-Fos-positive cells in the SFO depends on the route of Ang II administration. While a stimulation of periventricular AT receptors increases c-Fos mainly in the cells adjacent to the ventricle, intravenous injection of Ang II, which reaches the brain via the circumventricular organs which lack the blood brain barrier, results in stimulation of neurons and c-Fos induction in the central parts of the SFO (15, 16, 24) . Besides the SFO, regions like the PVN, SON or the MnPO display the same patterns of c-Fos expression to Ang II injected i.v. or icv (15, 16) . When Ang II is injected icv, the expression of transcription factors in the SON and PVN can, at least partly, be ascribed to the activation of AT receptors in the SFO and MnPO.
Lesions of the SFO or the anteroventricular region of the third ventricle were shown to inhibit Fos-like immunoreactivity in the SON and PVN (24, 31) . The half life of Ang II in the brain tissue and cerebrospinal fluid is very short, only few seconds, because the enzyme aminopeptidase A (APA; glutamyl aminopeptidase, EC 3. 4.11.7) catalyses the degradation of Ang II to angiotensin III (Ang III, (des-Asp 1 )-Ang II) (9) .
Both Ang II and Ang III bind with similar affinities to the two angiotensin receptor subtypes, AT 1 injections. The aminopeptidase inhibitor, amastatin, was used to determine which of the two angiotensin petides is more effective as inducer of transcription factor expression in the brain.
Methods

Animals
Male Wistar rats (280-300g BW) were obtained from Charles River, Sulzfeld, Germany. The animals were kept under controlled temperature, humidity and light/dark period and had free access to food and water.
Intracerebroventricular Injections
For intracerebroventricular (icv) injections, chronic cannulae were implanted into the lateral brain ventricle under chloralhydrate anaesthesia (400 mg/kg body weight, intraperitoneally). The animals were housed individually and were allowed a one week recovery period after surgery. During this time, rats were handled daily to avoid non-specific, stress-induced expression of transcription factors on the day of the experiment.
All icv injections were made between 8 and 11 a.m. in conscious, freely moving rats to avoid the interference of circadian rhythms with transcription factor expression.
The injection volume was 5 µl (1 µl substance, followed by 4 µl isotonic saline, or 5 µl isotonic saline in controls.
Rats were allocated to 9 groups (n=5 animals per group). Group 1 received isotonic saline. Group 2 received Ang II (100 pmol). Group 3 received Ang III (100 pmol).
Groups 4, 5, 6 and 7 received the AT 1 receptor antagonist losartan (10 nmol) or the AT 2 receptor antagonist PD 123 319 (5 nmol), respectively, alone or followed by Ang III (100 pmol). Group 8 and 9 received the aminopeptidase inhibitor amastatin (10 nmol) alone or in combination with Ang II (100 pmol), respectively. The inhibitors were injected 10 minutes before treatment with Ang III or Ang II. The doses of the antagonists were chosen according to the literature (3, 11, 28) .
Immunohistochemistry
Ninety minutes after the last injection, rats were deeply anaesthetised with chloralhydrate (400 mg/kg body weight, intraperitoneally) and perfused intracardially with phosphate-buffered saline, followed by 4% parafomaldehyde solution for the fixation of the brain tissue. Brains were removed, postfixed overnight in 4% paraformaldehyde and immersed in 30% sucrose for cryoprotection for three days.
Immunohistochemistry was performed on coronal, cryostat-cut, free floating slices (50 µm). Incubation with the primary antiserum was followed by detection using the conventional avidin-biotin complex peroxidase reaction with diaminobenzidine as chromogen as described before (12) . The dilutions of the antibodies were as follows:
anti-c-Fos 1:20 000; anti-c-Jun 1:1000; anti-Krox-24 1:4000. The secondary antibody, goat-anti-rabbit IgG (H+L), was used in a dilution of 1:400 according to the manufacturer`s instructions (Vectastain Kit, Vector Laboratories, Burlingame, Ca, U.S.A). For double immunohistochemistry, slices were first incubated with the antipeptide antiserum, followed by visualisation of the binding as described above with the vectastain SG substrate as chromogen. This was followed by incubation with the specific antisera against the transcription factors, visualized with DAB as chromogen.
The dilutions of the anti-peptide antisera were 1:5000 for anti-oxytocin and antiarginine vasopressin (AVP), 1:100 for anti-corticotropin releasing factor (CRF).
Drugs and antibodies used
Ang II and amastatin were purchased from Sigma-Aldrich (Taufkirchen, Germany), (Table 1) .
Krox 24
Ang II and Ang III were equipotent in stimulation of the Krox 24 expression (Table 1 ).
Compared to c-Fos and c-Jun, the Krox 24 expression was especially high in the SON. Other nuclei showed no differences between the expression of Krox 24 and the AP-1 transcription factors ( Table 1 ). The Ang III-induced Krox 24 expression was mediated by AT1 receptors, since pretreatment with losartan almost completely abolished the expression of this transcription factor in all four brain areas while pretreatment with PD123 319 had no effect (Table 1) (19) . Brain Ang III also seems to exert a tonic stimulatory control over arterial blood pressure (20) . Our results along with findings of others suggest that Ang III and not Ang II is the main effector peptide of the RAS in the brain.
In the present study, Ang II induced the expression of ITF also when its conversion to Ang III was inhibited. We employed a commercially available aminopeptidase A inhibitor, amastatin, which has been used in a number of previous studies (28) . This Therefore, the observed reduction of ITF expression to Ang II after pretreatment with amastatin is rather caused by lack of Ang III resulting from its decreased generation from Ang II than by a perturbation of Ang IV levels.
We report in the present study that, compared to controls, treatment with the AT 2 receptor antagonist PD123 319 alone increased c-Fos, c-Jun and Krox 24 in the PVN. The AT 2 receptor is G protein-coupled like the AT 1 receptor, and is predominantly expressed in the brain during foetal development. In most regions of the adult rat brain this receptor subtype is found at very low levels. Although the AT 2 receptor appears to be suppressed in the adult brain, few areas, such as the cerebellum, superior and inferior olive and the locus coeruleus display remarkable levels of AT 2 receptors (13). The AT 2 receptor has been implicated in such diverse processes as wound healing (it is e.g. up-regulated in the cortex after brain ischemia (14, 32) ), the regeneration and differentiation of neuronal tissue as well as apoptosis (7, 17, 21, 27) . The results of the present study demonstrate that AT 2 Expression of ITF was studied on coronal brain sections using polyclonal antisera followed by a peroxidase reaction with DAB as chromogen. The immunoreactive neurons were counted separately for each brain region with a computer program.
Values are expressed as means ± SD (n=5 animals per group). 
